Advertisement
Case Presentations of the Harvard Affiliated Emergency Medicine Residencies| Volume 48, ISSUE 4, P461-465, April 2015

Download started.

Ok

Petechiae, Anemia, and Thrombocytopenia

  • Karen A. Kinnaman
    Affiliations
    Department of Emergency Medicine, Harvard Medical School, Boston, Massachusetts

    Department of Emergency Medicine, Massachusetts General Hospital, Boston, Massachusetts
    Search for articles by this author
  • William D. Binder
    Affiliations
    Department of Emergency Medicine, Brown University School of Medicine, Providence, RI
    Search for articles by this author
  • Eric S. Nadel
    Affiliations
    Department of Emergency Medicine, Harvard Medical School, Boston, Massachusetts

    Department of Emergency Medicine, Massachusetts General Hospital, Boston, Massachusetts

    Department of Emergency Medicine, Brigham and Women's Hospital, Boston, Massachusetts
    Search for articles by this author
  • David F.M. Brown
    Correspondence
    Corresponding Address: David F. M. Brown, md, Department of Emergency Medicine, Massachusetts General Hospital, Founders 110, 55 Fruit Street, Boston, MA 02114
    Affiliations
    Department of Emergency Medicine, Harvard Medical School, Boston, Massachusetts

    Department of Emergency Medicine, Massachusetts General Hospital, Boston, Massachusetts
    Search for articles by this author
Published:February 04, 2015DOI:https://doi.org/10.1016/j.jemermed.2014.12.023
      Dr. Karen Kinnaman: Today's case is that of a 33-year-old man who presented to the Emergency Department (ED) complaining of an intense headache, weakness, and light-headedness.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of Emergency Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • George J.N.
        How I treat patients with thrombotic thrombocytopenic purpura: 2010.
        Blood. 2010; 116: 4060
        • Terrell D.R.
        • Williams L.A.
        • Vesely S.K.
        • Lämmle B.
        • Hovinga J.A.
        • George J.N.
        The incidence of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: all patients, idiopathic patients, and patients with severe ADAMTS-13 deficiency.
        J Thromb Haemost. 2005; 3: 1432-1436
        • Coppo P.
        • Bengoufa D.
        • Veyradier A.
        • et al.
        Severe ADAMTS13 deficiency in adult idiopathic thrombotic microangiopathies defines a subset of patients characterized by various autoimmune manifestations, lower platelet count, and mild renal involvement.
        Medicine (Baltimore). 2004; 83: 233-244
        • Vesely S.K.
        • George J.N.
        • Lämmle B.
        • et al.
        ADAMTS13 activity in thrombotic thrombocytopenic purpura–hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients.
        Blood. 2003; 102: 60-68
        • Ridolfi R.L.
        • Bell W.R.
        Thrombotic thrombocytopenic purpura. Report of 25 cases and review of the literature.
        Medicine (Baltimore). 1981; 60: 413-428
        • Allford S.L.
        • Hunt B.J.
        • Rose P.
        • Machin S.J.
        Guidelines on the diagnosis and managementof the thrombotic microangiopathichaemolyticanaemias.
        Br J Haematol. 2003; 120: 556-573
        • Moake J.L.
        Thrombotic microangiopathies.
        N Engl J Med. 2002; 347: 589-600
        • Tarr P.I.
        • Gordon C.A.
        • Chandler W.L.
        Shiga-toxin-producing Escherichia coli and haemolyticuraemic syndrome.
        Lancet. 2005; 365: 1073-1078
        • Garg A.X.
        • Suri R.S.
        • Barrowman N.
        • et al.
        Long-term renal prognosis of diarrheaassociated hemolytic uremic syndrome: a systematic review, meta-analysis, and meta-regression.
        JAMA. 2003; 290: 1360-1370
        • Furlan M.
        • Robles R.
        • Solenthaler M.
        • Wassmer M.
        • Sandoz P.
        • Lämmle B.
        Deficient activity of von Willebrand factor cleaving protease in chronic relapsing thrombotic thrombocytopenic purpura.
        Blood. 1997; 89: 3097-3103
        • Rock G.A.
        • Shumak K.H.
        • Buskard N.A.
        • et al.
        Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group.
        N Engl J Med. 1991; 325: 393-397
        • Sadler J.E.
        Von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenicpurpura.
        Blood. 2008; 112: 11-18
        • George J.N.
        Thrombotic thrombocytopenic purpura.
        N Engl J Med. 2006; 354: 1927-1935
        • Swisher K.K.
        • Terrell D.R.
        • Vesely S.K.
        • Kremer Hovinga J.A.
        • Lämmle B.
        • George J.N.
        Clinical outcomes after platelet transfusions in patients with thrombotic thrombocytopenic purpura.
        Transfusion. 2009; 49: 873-887
        • Tsai H.M.
        The molecular biology of thrombotic microangiopathy.
        Kidney Int. 2006; 70: 16-23
        • Zheng X.L.
        • Kaufman R.M.
        • Goodnough L.T.
        • Sadler J.E.
        Effect of plasma exchange on plasma ADAMTS13 metalloprotease activity, inhibitor level, and clinical outcome in patients with idiopathic and nonidiopathic thrombotic thrombocytopenic purpura.
        Blood. 2004; 103: 4043-4049
        • George J.N.
        How I treat patients with thrombotic thrombocytopenic purpura–hemolytic uremic syndrome.
        Blood. 2000; 96: 1223-1229
        • Ruggenenti P.
        • Noris M.
        • Remuzzi G.
        Thrombotic microangiopathy, hemolytic uremic syndrome, and thrombotic thrombocytopenic purpura.
        Kidney Int. 2001; 60: 831-846
        • Amorosi E.L.
        • Ultmann J.E.
        Thrombotic thrombocytopenic purpura: report of 16 cases and review of the literature.
        Medicine (Baltimore). 1966; 45: 139-159
        • Galbusera M.
        • Bresin E.
        • Noris M.
        • et al.
        Rituximab prevents recurrence of thrombotic thrombocytopenic purpura: a case report.
        Blood. 2005; 106: 925-928
        • Bell W.R.
        • Braine H.G.
        • Ness P.M.
        • Kickler T.S.
        Improved survival in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Clinical experience in 108 patients.
        N Engl J Med. 1991; 325: 398-403
        • Chemnitz J.
        • Draube A.
        • Scheid C.
        • et al.
        Successful treatment of severe thrombotic thrombocytopenic purpura with the monoclonal antibody rituximab.
        Am J Hematol. 2002; 71: 105-108